

Product Data Sheet

Product Name: OSMI-4
Cat. No.: GC31517

Chemical Properties

Cas. No. 2260791-14-6

SMILES O=C1C=CC2=C(C=C(Cl)C(S(N[C@@H](C(N(CC(OCC)=O)CC3=CC=CS3)=O)C4=C(OC)C=CC=C4)(=O)=O)=C2)N1


Formula $C_{27}H_{26}ClN_3O_7S_2$ M.Wt 604.09

Solubility DMSO : 125 mg/mL (206.92 mM) Storage Store at -20°C

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure



Protocol

Cell experiment [1]:

Cell lines	Neural stem cells (NSCs) from SD rats
------------	---------------------------------------

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Preparation Method	Rat NSCs were cultured in DMEM/F12 medium, supplemented with 2% B-27 supplements, 20ng/ml EGF, 20ng/ml FGF, 100U/ml penicillin, and 100U/ml streptomycin at 37°C in an incubator with 5% CO ₂ . Cells were seeded onto polyornithine-laminin-coated 24-well plates with a density of 3×10 ⁴ cells/well. After 24h culture, the medium with different concentrations of OSMI-4 (0, 0.2, 1, and 2μM) was added. After 7 days of culture, the differentiation of the NSCs was evaluated through immunofluorescent staining.
Reaction Conditions	0, 0.2, 1, and 2μM; 7 days
Applications	OSMI-4 treatment enhanced the differentiation of the rat NSCs in a dose-dependent manner, accompanied by an increase in MAP2 ⁺ cells and Tuj1 ⁺ cells.
Animal experiment [2]:	
Animal models	Female BALB/c nude mice
Preparation Method	Female BALB/c nude mice (4 weeks old; 22-25g) were used. Each mouse was subcutaneously injected with 1×10 ⁶ TE10 cells suspended in 200μl of sterile PBS. Tumor growth was monitored twice weekly by measuring dimensions with calipers, and volume was calculated using the formula 0.5×length×width ² . When tumors reached 150mm ³ , mice were randomized into treatment groups. OSMI-4 was administered daily at 20mg/kg via intraperitoneal injection for 20 days. At the end of the experiment, mice were euthanized, and tumors were excised for analysis.
Dosage form	20mg/kg/day; 20 days; i.p.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Applications	OSMI-4 significantly inhibited the tumor volume in mice with TE10 xenografts.
References: [1] Liu X, Song S, Chen Z, et al. Release of O-GlcNAc transferase inhibitor promotes neuronal differentiation of neural stem cells in 3D bioprinted supramolecular hydrogel scaffold for spinal cord injury repair[J]. Acta biomaterialia, 2022, 151: 148-162. [2] Liu J, Cao D, Xu T, et al. O-GlcNAcylation stabilizes RSK4 by antagonizing GSK3β-mediated phosphorylation to enhance radioresistance in esophageal squamous cell carcinoma[J]. International Journal of Biological Sciences, 2026, 22(5): 2418.	

Background

OSMI-4 is a potent O-GlcNAc transferase (OGT) inhibitor, with an EC₅₀ value of 3 μ M^[1]. OSMI-4 suppresses the catalytic activity of OGT, reduces the overall level of O-GlcNAc protein modification, and impairs homologous recombination repair and cell cycle progression^[2]. OSMI-4 has been widely used in tumor research to reduce the overall O-GlcNAc levels and regulate cellular metabolic activity^[3].

In vitro, OSMI-4 (2 μ M) incubated for 7 days induced the differentiation of rat neural stem cells and enhanced cell viability^[4]. Treatment with 30 μ M OSMI-4 for 24 hours increased the levels of p62 and LC3-II proteins in CCD841CoN cells and disrupted the intracellular localization of lysosomes^[5]. Treatment with 20 μ M OSMI-4 for 24 hours induced cell cycle arrest in HCT116 cells, resulting in increased expression of γ H2AX, cleaved caspase 7, and cleaved PARP-1^[6].

In vivo, OSMI-4 administration via intraperitoneal injection at a dose of 200 μ g every three days for 2 weeks markedly inhibited tumor growth and enhanced the number of cytotoxic CD8⁺ T cells in the tumor tissue of Hepa1-6 xenograft mice^[7]. Daily intraperitoneal injection of OSMI-4 (20mg/kg) for 20 days, combined with two rounds of localized X-ray irradiation (5Gy), significantly inhibited the tumor volume of TE10 xenograft mice^[8].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

References:

- [1] Martin S E S, Tan Z W, Itkonen H M, et al. Structure-Based Evolution of Low Nanomolar O-GlcNAc Transferase Inhibitors[J]. Journal of the American Chemical Society, 2018, 140(42): 13542-13545.
- [2] Ping X, Stark J M. O-GlcNAc transferase is important for homology-directed repair[J]. DNA repair, 2022, 119: 103394.
- [3] Loi E M, Weiss M, Pajk S, et al. Intracellular hydrolysis of small-molecule O-linked N-acetylglucosamine transferase inhibitors differs among cells and is not required for its inhibition[J]. Molecules, 2020, 25(15): 3381.
- [4] Liu X, Song S, Chen Z, et al. Release of O-GlcNAc transferase inhibitor promotes neuronal differentiation of neural stem cells in 3D bioprinted supramolecular hydrogel scaffold for spinal cord injury repair[J]. Acta biomaterialia, 2022, 151: 148-162.
- [5] Ahmed A B, Scache J, Mortuaire M, et al. Downregulation of O-GlcNAc transferase activity impairs basal autophagy and late endosome positioning under nutrient-rich conditions in human colon cells[J]. Biochemical and Biophysical Research Communications, 2024, 724: 150198.
- [6] Loison I, Pioger A, Paget S, et al. O-GlcNAcylation inhibition redirects the response of colon cancer cells to chemotherapy from senescence to apoptosis[J]. Cell Death & Disease, 2024, 15(10): 762.
- [7] Zhu Q, Wang H, Chai S, et al. O-GlcNAcylation promotes tumor immune evasion by inhibiting PD-L1 lysosomal degradation[J]. Proceedings of the National Academy of Sciences, 2023, 120(13): e2216796120.
- [8] Liu J, Cao D, Xu T, et al. O-GlcNAcylation stabilizes RSK4 by antagonizing GSK3 β -mediated phosphorylation to enhance radioresistance in esophageal squamous cell carcinoma[J]. International Journal of Biological Sciences, 2026, 22(5): 2418.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA